Entero Therapeutics Files 8-K: Agreements, Officer Changes, Financials
Ticker: GRDX · Form: 8-K · Filed: Sep 12, 2025 · CIK: 1604191
| Field | Detail |
|---|---|
| Company | Entero Therapeutics, Inc. (GRDX) |
| Form Type | 8-K |
| Filed Date | Sep 12, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $12,500 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, officer-changes, director-changes, financials
TL;DR
Entero Therapeutics (ENTX) filed an 8-K detailing new agreements, exec departures/appointments, and financials.
AI Summary
Entero Therapeutics, Inc. announced on September 12, 2025, the entry into a material definitive agreement. The company also reported the departure of directors or certain officers, the election of directors, and the appointment of certain officers, along with compensatory arrangements for these officers. Financial statements and exhibits were also filed as part of this report.
Why It Matters
This 8-K filing indicates significant corporate actions including new agreements and changes in leadership, which could impact the company's strategic direction and operational stability.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and changes in corporate officers, which can introduce uncertainty and potential risks.
Key Players & Entities
- Entero Therapeutics, Inc. (company) — Registrant
- September 12, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-37853 (identifier) — SEC file number
- 46-4993860 (identifier) — EIN
- First Wave BioPharma, Inc. (company) — Former company name
- AzurRx BioPharma, Inc. (company) — Former company name
- BioPharma d'Azur, Inc. (company) — Former company name
FAQ
What type of material definitive agreement did Entero Therapeutics enter into?
The filing states that Entero Therapeutics, Inc. entered into a material definitive agreement, but the specific details of the agreement are not provided in this excerpt.
What specific changes occurred regarding directors and officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers, along with compensatory arrangements for these officers.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on September 12, 2025.
What are the former names of Entero Therapeutics, Inc.?
Entero Therapeutics, Inc. was formerly known as First Wave BioPharma, Inc. (name change on 20210921), AzurRx BioPharma, Inc. (name change on 20141103), and BioPharma d'Azur, Inc. (name change on 20140331).
What is the SIC code for Entero Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Entero Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 648 words · 3 min read · ~2 pages · Grade level 11 · Accepted 2025-09-12 16:30:55
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ENTO Nasdaq Capital Marke
- $12,500 — o which he will receive compensation of $12,500 per month. The Company will also defend
Filing Documents
- tm2525441d2_8k.htm (8-K) — 27KB
- tm2525441d2_ex10-1.htm (EX-10.1) — 34KB
- 0001104659-25-089562.txt ( ) — 232KB
- fwbi-20250912.xsd (EX-101.SCH) — 3KB
- fwbi-20250912_lab.xml (EX-101.LAB) — 33KB
- fwbi-20250912_pre.xml (EX-101.PRE) — 22KB
- tm2525441d2_8k_htm.xml (XML) — 4KB
01. Entry Into a Material Definitive
Item 1.01. Entry Into a Material Definitive Agreement The information set forth in Item 5.02 below regarding the CEO Agreement (as defined below) is incorporated by reference in this Item 1.01.
02. Departure of Directors or Certain
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Entry into Consulting Agreement for appointment of Jason D. Sawyer as CEO As previously disclosed on the Current Report on Form 8-K filed with the Securities and Exchange Commission on September 9, 2025, the Company had appointed Mr. Jason D. Sawyer as Interim Chief Executive Officer of the Company. Subsequently, on September 8, 2025, the Company entered into a consulting agreement in connection with Mr. Sawyer's role as interim CEO (the "CEO Agreement"), effective as of September 4, 2025, pursuant to which he will receive compensation of $12,500 per month. The Company will also defend and indemnify Mr. Sawyer in his capacity as Chief Executive Officer of the Company to the fullest extent permitted under the Delaware General Corporation Law ("DGCL") and shall also maintain a policy for indemnifying its officers and directors, including Mr. Sawyer, for all actions permitted under the DGCL taken in good faith pursuit of their duties for the Company. The foregoing description of the CEO Agreement does not purport to be complete and is qualified in its entirety by the terms of the CEO Agreement, which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Consulting Agreement dated S eptember 8 , 2025 between Company and Access Alternative Group S.A. for appointment of Jason D. Sawyer as Chief Executive Officer of the Company. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Entero Therapeutics, Inc. September 12, 2025 By: /s/ Jason D. Sawyer Name: Jason D. Sawyer Title: Interim Chief Executive Officer